Uptravi Boost to Pulmonary Arterial Hypertension (PAH) Market to Be Game Changer: Transparency Market Research

ALBANY, N.Y.--()--Transparency Market Research has recently published a research document titled “Pulmonary Arterial Hypertension (PAH) Market (Prostacyclin and Prostacyclin Analogs, ERAs, PDE-5 Inhibitors, sGC Stimulators and Selexipag) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”.

Browse Report: http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html

According to the report, the global pulmonary arterial hypertension (PAH) market is currently growing at a CAGR of 2.3% from 2014 to 2020. The market’s value prior to this analysis window was US$4.04 billion in 2013. The report estimates that the global pulmonary arterial hypertension (PAH) market will reach US$5.19 billion by 2020.

Request Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1181

The report provides a segment description of the global pulmonary arterial hypertension (PAH) market in terms of its commercially available drug classes: soluble guanylate cyclase (sGC) stimulators, phosphodiesterase-5 (PDE-5) inhibitors, endothelin receptor antagonists (ERAs) and prostacyclin and prostacyclin analogs. Prostacyclin and prostacyclin analogs were the first U.S. FDA approved drugs to be introduced in the global pulmonary arterial hypertension market. The drugs currently being sold under this category are iloprost, treprostinil and epoprostenol. These three drugs are the most widely used in the treatment of PAH.

Press Release: http://www.transparencymarketresearch.com/pressrelease/pulmonary-arterial-hypertension-therapeutics-market.htm

The report also says that the imminent release of the PAH drug called Uptravi (selexipag) in 2016 could potentially drive the growth of the global pulmonary arterial hypertension market till 2020.

Dominant players in the global pulmonary arterial hypertension (PAH) market include United Therapeutics Corporation, Pfizer, Inc., GSK Plc, Gilead Sciences, Inc., and Actelion Pharmaceuticals, Ltd. Of these, Actelion Pharma held the largest share in the global PAH market in 2013 on account of its bestselling product, Tracleer (bosentan).

Bayer HealthCare has a substantial potential for growth due to the release of its new PAH drug, Adempas (riociguat).

Other Reports:

About Transparency Market Research

Transparency Market Research (TMR) is a U.S. based market intelligence company driven by high-pedigree consultants and researchers. TMR leverages its Syndicated Research, Custom Research, and Market Consulting expertise to help businesses make accurate decisions. TMR’s exclusive blend of quantitative forecasting and trends analysis draws on proprietary data sources and techniques, while their data repository is continuously updated to reflect the latest trends.

Contacts

Transparency Market Research
Mr. Nachiket Ghumare, +1-518-618-1030
USA-Canada Toll Free: 866-552-3453
sales@transparencymarketresearch.com
http://www.transparencymarketresearch.com/

Release Summary

Pulmonary Arterial Hypertension (PAH) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Contacts

Transparency Market Research
Mr. Nachiket Ghumare, +1-518-618-1030
USA-Canada Toll Free: 866-552-3453
sales@transparencymarketresearch.com
http://www.transparencymarketresearch.com/